576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients

BACKGROUND: Observational studies suggest that half-dose valganciclovir (VGV) prophylaxis (450 mg daily for normal renal function) is as effective as full-dose (900 mg daily) in preventing CMV infection among kidney transplant recipients (KTR). However, this practice is not supported by current guid...

Descripción completa

Detalles Bibliográficos
Autores principales: shi, yiyun, Rogers, Ralph, Vieira, Kendra, Merhi, Basma, Osband, Adena, Bayliss, George, Gohh, Reginald, Morrissey, Paul, Farmakiotis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777334/
http://dx.doi.org/10.1093/ofid/ofaa439.770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777334/
http://dx.doi.org/10.1093/ofid/ofaa439.770

Ejemplares similares